How well do you know your CV outcomes trial data for novel type 2 diabetes drugs? Your answers to these 8 questions will tell.
In December 2018, in recognition of the reality that many patients cared for by CV clinicians have known type 2 diabetes mellitus (T2DM) as well as atherosclerotic cardiovascular disease (ASCVD), the American College of Cardiology published its expert consensus decision pathway on novel therapies for cardiovascular risk reduction in patients with type 2 diabetes and atherosclerotic cardiovascular disease. The document summarizes key elements of published cardiovascular outcome ttrials and provides guidance on use of sodium glucose cotransporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 receptor agonists (GLP-1RA) in the prevention of CV morbidity and mortality in patients with T2DM.
The following questions are based on this consensus document.
Question 1. Large randomized clinical trials of SGLT2 inhibitors conducted in patients with T2DM most with established ASCVD, have demonstrated that 2 drugs in the class reduce major adverse cardiovascular events (MACE) and HF hospitalization; they are:
A. Dapagliflozin and empagliflozin
B. Empagliflozin and canagliflozin
C. Canagliflozin and ertugliflozin
D. Ertugliflozin and dapagliflozin
Source: Das SR, Everett BM, Birtcher KK, et al. 2018 ACC expert consensus decision pathway on novel therapies for cardiovascular risk reduction in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. J Am Coll Cardiol. 2018;72:3200–3223.